Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Nature Communications|November 15, 2014
Genomic landscape of metastatic colorectal cancerJosien C Haan, Mariette Labots, Christian Rausch, et al.
The Journal of Pathology|May 15, 2024
Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapyBirgit S Geurts, Laurien J Zeverijn, Jade M van Berge Henegouwen, et al.
The Oncologist|September 19, 2025
SUNRISE-CRC: a randomized phase II study of high-dose intermittent sunitinib versus trifluridine/tipiracil in metastatic colorectal carcinomaJorien B E Janssen, Kirti K Iyer, Sophie L Gerritse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2025
Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal CancerSophie L Gerritse, Erik J van Helden, Anne I J Arens, et al.
Nature Genetics|October 2, 2019
The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequenciesLindsay Angus, Marcel Smid, Saskia M Wilting, et al.
The Oncologist|June 4, 2020
Safety and Feasibility of Additional Tumor Debulking to First-Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal CancerElske C Gootjes, Eric P van der Stok, Tineke E Buffart, et al.
European Journal of Cancer (Oxford, England : 1990)|July 11, 2024
Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanomaIsabella A J van Duin, Mark Schuiveling, Laurens S Ter Maat, et al.
Clinical Proteomics|February 19, 2021
Time dependent effect of cold ischemia on the phosphoproteome and protein kinase activity in fresh-frozen colorectal cancer tissue obtained from patientsTineke E Buffart, Rosanne A H M van den Oord, Adriënne van den Berg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2021
Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor TypesHanneke van der Wijngaart, Louisa R Hoes, J Maxime van Berge Henegouwen, et al.
The Lancet Regional Health. Europe|March 11, 2024
Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access ProtocolKarlijn Verkerk, Birgit S Geurts, Laurien J Zeverijn, et al.
Pageof 6